Targeting p53 in chronic lymphocytic leukemia

References

• Teras LR, DeSantis CE, Cerhan J, et al. 2106 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Hallek M, Shanafelt TD, Eichhorst B, et al. Chronic lymphocytic leukemia. Lancet. 2018;391(10129):1524–1537.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017;2017(1):329–337.
   PubMedGoogle Scholar
• Duffy MJ, Crown J. Drugging “Undruggable” genes for cancer treatment: are we making progress?Int J Cancer. 2020 Online ahead of print.].
   Google Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanism of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–370.
   PubMed Web of Science ®Google Scholar
• Aylon Y, Oren M. The paradox of p53: what, how and why? Cold Spring Harb Perspect Med. 2016;6(10):a026328.
   PubMed Web of Science ®Google Scholar
• Hafner A, Bulyk ML, Jambhekar A, et al. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199–210.
   PubMed Web of Science ®Google Scholar
• Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015;16(7):393–405.
   PubMed Web of Science ®Google Scholar
• Walker KK, Levine AJ. Identification of a novel p53 domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 1996;93(26):15335–15340.
   PubMed Web of Science ®Google Scholar
• Weinberg RL, Veprintserv DB, Fersht AR, et al. Cooperative binding of tetrameric p53 to DNA. J Mol Biol. 2004;341(5):1145–1159.
   PubMed Web of Science ®Google Scholar
• Clore GM, Ernst J, Clubb R, et al. Refined solution structure of the oligomerization domain of the tumor suppressor p53. Nat Struct Biol. 1995;2:321–333.
   PubMedGoogle Scholar
• Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11(7):564–577.
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13(1):49–58.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2(8):594–604.
   PubMed Web of Science ®Google Scholar
• Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9(5):573–580.
   PubMed Web of Science ®Google Scholar
• Tarapore P, Horn HF, Tokuyama Y, et al. Direct regulation of the centrosome duplication cycle by the p53-p21 Waf1/Cip1 pathway. Oncogene. 2001;20(25):3173–3184.
   PubMed Web of Science ®Google Scholar
• Valdez JM, Nichols KE, Kesserwan C. Li-fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Hematol. 2017:539–552.
   PubMed Web of Science ®Google Scholar
• Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15(1):13–30.
   PubMed Web of Science ®Google Scholar
• Spunarova M, Tom N, Pavlova S, et al. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: clinical practice experience. Leuk Res. 2019;81:75–81.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 2008;22(7):1456–1459.
   PubMed Web of Science ®Google Scholar
• Navrkalova V, Sebejova L, Zemanova J, et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. Haematologica. 2013;98(7):1124–1131.
   PubMed Web of Science ®Google Scholar
• Leroy B, Ballinger ML, Baran-Marszac F, et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res. 2017;77(6):1250–1260.
   PubMed Web of Science ®Google Scholar
• Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672–688.
   PubMed Web of Science ®Google Scholar
• De Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA. 2002;99(5):2948–2953.
   PubMed Web of Science ®Google Scholar
• Pfister NT, Prives C. Trascriptional regulation by wild-type and cancer-related mutant forms of p53. Cold Spring Harb Perspect Med. 2017;7(2):a026054.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol. 2011;29(19):2703–2708.
   PubMed Web of Science ®Google Scholar
• Cerna K, Oppelt J, Chochola V, et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33(2):403–414.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong JZ, et al. P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 1991;88:5413–5417.
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714–726.
   PubMed Web of Science ®Google Scholar
• Catherwood MA, Gonzalez D, Donaldson D, et al. Relevance of TP53 for CLL diagnostics. J Clin Pathol. 2019;72(5):343–346.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–2760.
   PubMed Web of Science ®Google Scholar
• Malcikova J, Tausch E, Rossi D, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation. Leukemia. 2018;32(5):1070–1080.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761–2772.
   PubMed Web of Science ®Google Scholar
• Pal K, Bystry V, Reigl T, et al. European Research Initiative on CLL (ERIC)—TP53 Network, GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data. Bioinformatics. 2017;33(23):3802–3804.
   PubMed Web of Science ®Google Scholar
• Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123:2139–2147.
   PubMed Web of Science ®Google Scholar
• Blakemore SJ, Clifford R, Parker H, et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. Leukemia. 2020;34(7):1760–1774.
   PubMed Web of Science ®Google Scholar
• Te Raa GD, Malčiková J, Mraz M, et al. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. Br J Haematol. 2014;167(4):565–569.
   PubMed Web of Science ®Google Scholar
• Carter A, Lin K, Sherrington PD, et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol. 2004;127(4):425–428.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801–3808.
   PubMed Web of Science ®Google Scholar
• Condoluci A, Terzi Di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859–1869.
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–530.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–3254.
   PubMed Web of Science ®Google Scholar
• Rossi D, Terzi-Di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–1924.
   PubMed Web of Science ®Google Scholar
• Estenfelder S, Tausch E, Robrecht S, et al. Gene mutations and treatment outcome in the context of chlorambucil (Clb) without or with the addition of rituximab (R) or obinutuzumab (GA-101, G) - Results of an extensive analysis of the phase III study CLL11 of the German CLL study group. Blood. 2016;128:3227.
   Web of Science ®Google Scholar
• Bagacean C, Tempescul A, Ternant D, et al. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer. 2019;7(1):22.
   PubMedGoogle Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23(1):212–214.
   PubMed Web of Science ®Google Scholar
• Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114(5):957–964.
   PubMed Web of Science ®Google Scholar
• International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30(14):1647–1655.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357–2366.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–1919.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.
   PubMed Web of Science ®Google Scholar
• Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135(26):2402–2412.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–2236.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–1402.
   PubMed Web of Science ®Google Scholar
• Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672.
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015;373:220–231.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377:2024–2035.
   PubMed Web of Science ®Google Scholar
• Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809–1819.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282–288.
   PubMed Web of Science ®Google Scholar
• Lambert JMR, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15:376–388.
   PubMed Web of Science ®Google Scholar
• Nahi H, Lehmann S, Mollgard L, et al. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol. 2004;127:285–291.
   PubMed Web of Science ®Google Scholar
• Nahi H, Selivanova G, Lehmann S, et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol. 2008;141:445–453.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Descamps G, Moreau P, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood. 2014;124:1626–1636.
   PubMed Web of Science ®Google Scholar
• Maslah N, Salomao N, Drevon L, et al. Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2020;105(6):1539–1551.
   PubMed Web of Science ®Google Scholar
• Jaskova Z, Pavlova S, Malcikova J, et al. PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells. Leuk Res. 2020;89:106288.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
   PubMed Web of Science ®Google Scholar
• Lia Floquet C, Deforges J, Rousset J-P, et al. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res. 2011;39(8):3350–3362.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–299.
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the P53 pathway. Nat Rev Cancer. 2009;9(12):862–873.
   PubMed Web of Science ®Google Scholar
• Vu B, Wovkulich P, Pizzolato G, et al. Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett. 2013;56:5979–5983.
   Google Scholar
• Ding Q, Zhang Z, JJ L, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979–5983.
   PubMed Web of Science ®Google Scholar
• Drakos E, Singh RR, Rassidakis GZ, et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011;25(5):856–867.
   PubMed Web of Science ®Google Scholar
• Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605–613.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133–1140.
   PubMed Web of Science ®Google Scholar
• Andreeff M, Kelly KR, Yee K, et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2016;22(4):868–876.
   PubMed Web of Science ®Google Scholar
• Verreault M, Schmitt C, Goldwirt L, et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin Cancer Res. 2016;22(5):1185–1196.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525–533.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Beckermann BM, Catalani O, et al. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 2020;16(13):807–815.
   PubMed Web of Science ®Google Scholar
• Ciardullo C, Aptullahoglu E, Woodhouse L, et al. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica. 2019;104(12):2429–2442.
   PubMed Web of Science ®Google Scholar
• Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):61.
   PubMed Web of Science ®Google Scholar
• García-Santisteban I, Arregi I, Alonso-Mariño M, et al. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell Mol Life Sci. 2016;73(24):4685–4699.
   PubMed Web of Science ®Google Scholar
• Subhash VV, Yeo MS, Wang L, et al. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 2018;8(1):12248.
   PubMedGoogle Scholar
• Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127(5):582–595.
   PubMed Web of Science ®Google Scholar
• Boudny M, Zemanova J, Khirsariya P, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019;104(12):2443–2455.
   PubMed Web of Science ®Google Scholar
• Moia R, Patriarca A, Schipani M, et al. Precision medicine management of chronic lymphocytic leukemia. Cancers (Basel). 2020;12(3):642.
   Web of Science ®Google Scholar
• Moia R, Patriarca A, Deambrogi C, et al. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(2):109–116.
   PubMed Web of Science ®Google Scholar
• Zhu J, Sammons MA, Donahue G, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525(7568):206–211.
   PubMed Web of Science ®Google Scholar
• Lau R, Niu MY, Pratt MA. cIAP2 represses IKK/-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle. 2012;11(21):4009–4019.
   PubMed Web of Science ®Google Scholar
• Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020;105(2):448–456.
   PubMed Web of Science ®Google Scholar
• Moia R, Patriarca A, Mahmoud AM, et al. Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. Expert Opin Orphan Drugs. 2020;8(9):329–342.
   Web of Science ®Google Scholar